Helixmith

Helixmith is a biotechnology company headquartered in Seoul, Korea, with a branch office in San Diego, USA. The company boasts an extensive gene therapy pipeline, including non-viral plasmid DNA projects for neuromuscular and ischemic diseases, CAR-T projects targeting several types of solid tumors, and AAV vector projects for neuromuscular disorders. Helixmith's lead gene therapy product is Engensis, currently in Phase III clinical trials in the United States for diabetic peripheral neuropathy. Engensis is a plasmid DNA designed to simultaneously express two isoforms of hepatocyte growth factor, HGF 728 and HGF 723.